Invitation to attend Vitrolife's conference call regarding presentation of the interim report January- March 2022. The presentation will be held in English.

Time: Friday 22 April, 2022 at 10.00 a.m. CET.

Registration can preferably be done 10-15 minutes before the conference start time on:

Sweden dial in number: +46 (0)8 506 921 69
International dial in number: +44 (0) 2030 095709
Conference name: Vitrolife, conference ID: 6938009
Event Passcode: 6938009

Vitrolife participants:
Thomas Axelsson, CEO
Patrik Tolf, CFO

The press release for Vitrolife's interim report will be released at 8.00 CET on the same day.

Before the conference call, presentation material will be available at the company web page, https://www.vitrolife.com/investors/Presentations/

A recorded version of the telephone conference will be available for seven days on number +44 (0) 333 300 9785 (International), access code 6938009.

Gothenburg, 8 April 2022
VITROLIFE AB (publ)

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife is supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,200 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aims to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

https://news.cision.com/vitrolife-ab--publ-/r/conference-call-interim-report,c3542617

https://mb.cision.com/Main/1031/3542617/1561638.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English